Regulations, patent dispute will determine CRISPR’s affordability, future in agriculture

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.

Plant breeders have long been split into two camps: those who use genetic modification, and those who don’t. But if gene editing continues to skirt regulations, that divide may become more of a spectrum than a split. Because, while some breeders are philosophically opposed to using genetic engineering, the red tape and expense involved are often the larger factors keeping them from using the technology.

. . . .

There’s the breeding of crops, explains [Charlie Brummer, an alfalfa breeder at University of California, Davis], “then there’s the legal landscape that undergirds everything and that can limit what can be done.” With the patent on CRISPR technology still playing out in courts, the expenses—namely, the possible royalty payments for any resulting seed patents—are not yet fully known.

If it remains affordable, however, technologies like CRISPR could then give breeders a new tool that could in theory greatly speed up the breeding process and potentially be done cheaply, without the oversight generally required for genetic modification. But whether breeders want that door open is a different question.

Read full, original post: Could CRISPR Gene Editing Change the Future of Ag?

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Screenshot 2026-05-26 at 10.15
Viewpoint: Double standard—Why does the wellness industry get a free pass while Big Healthcare is treated as morally suspect?
ChatGPT-Image-Jun-4-2026-11_49_36-AM-2
‘You don’t understand Tolkien’: Skeptic Pope trolls tech giants about the exaggerated, risk-less benefits of AI
Screenshot-2026-06-04-at-12.05.08-PM
Cases of brain inflammation surge as U.S. measles pandemic approaches 2000
ChatGPT-Image-Jun-4-2026-01_27_58-PM
Viewpoint—N.A.D.+: Why Gwenyth Paltrow’s heralded anti-aging supplement doesn’t work
Screenshot 2025-07-30 at 10.48
Can gene editing eliminate Down syndrome? Scientists have done it in lab-grown cells
ChatGPT Image May 26, 2026, 08_42_17 AM (1)
Viewpoint: Greenpeace and poison: How environmental advocacy groups rely on compliant (and often ignorant) journalists to spread disinformation and spark litigation
Screenshot-2026-06-03-at-1.24.46-PM
Challenging anti-GMO disinformation: Why genetically-tweaked crops offer bushels of benefits
ChatGPT-Image-Mar-10-2026-01_39_01-PM
Viewpoint—“Miracle molecule” debunked: Why acemannan supplements don’t work
downsyndrome_compilation_MID_1
CRISPR breakthrough that can remove the chromosome responsible for Down syndrome raises ethical questions
ChatGPT Image May 26, 2026, 08_21_36 AM
Limiting gender affirming interventions: Trump administration targets Texas even though it already bans youth access
Screenshot 2026-06-04 at 12.43
Viewpoint: Doctors who are battling Ebola are incredulous that U.S. government is not utilizing specially designed emergency health units meant to fight virulent disease
tick-DNA
GLP podcast: Spread meat allergy with gene-edited ticks? Bioethicists pose vile ‘thought experiment’
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.